EFSA J. 2023 Feb 16;21(2):e07807. doi: 10.2903/j.efsa.2023.7807. eCollection 2023 Feb.
On 26 August 2022, the European Commission asked EFSA to provide scientific and technical assistance according to Article 21(2) of Regulation (EC) No 1107/2009 concerning the review of the approval of the active substance pirimicarb and to deliver a statement on whether the applicable approval criteria may still be considered fulfilled, taking into consideration the information submitted by the applicant and the assessment of the rapporteur Member State, Sweden and, where applicable, the results of a discussion with experts from Member States. The current statement contains a summary of the main findings of the assessment of the risks to consumers from the exposure to metabolites of pirimicarb through dietary intake, the risks to human health through non-dietary exposure and the acute risk to birds from the representative uses of pirimicarb assessed for the first approval and additionally, from the representative uses as submitted as part of the renewal of approval. Concerns are reported where identified.
2022年8月26日，欧盟委员会要求欧洲食品安全局根据关于审查活性物质抗蚜威批准情况的（EC）No 1107/2009号条例第21(2)条提供科学和技术援助，并就是否仍可认为适用的批准标准得到满足发表声明，同时考虑申请人提交的信息、报告成员国瑞典的评估以及在适用情况下与成员国专家讨论的结果。本声明总结了评估通过饮食摄入抗蚜威代谢物对消费者造成的风险、非饮食接触对人类健康造成的风险以及首次批准时评估的抗蚜威代表性用途对鸟类的急性风险，此外还总结了作为批准续期一部分提交的代表性用途的相关风险。如有发现问题，将予以报告。
